Company Description
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.
The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.
Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.
Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Laurent Fischer |
Contact Details
Address: 100 Cardinal Way Redwood City, California 94063 United States | |
| Phone | 650 656 9323 |
| Website | adverum.com |
Stock Details
| Ticker Symbol | ADVM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501756 |
| CUSIP Number | 00773U108 |
| ISIN Number | US00773U1088 |
| Employer ID | 20-5258327 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Laurent Fischer | President, Chief Executive Officer and Director |
| Linda M. Rubinstein M.A. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Kishor Peter Soparkar J.D. | Chief Operating Officer |
| Dr. Setareh Seyedkazemi Pharm.D. | Chief Development Officer |
| Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer |
| Dr. R. Andrew Ramelmeier Ph.D. | Chief Technology Officer |
| Dr. Romuald Corbau Ph.D. | Chief Scientific Officer |
| John W. Rakow J.D. | Senior Vice President and General Counsel |
| Dena House | Chief People Officer |
| Carla Fiankan | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 31, 2024 | SCHEDULE 13G | Filing |